Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway

Wang,Weihong; He,Yukai; Liu,Qiuli

doi:10.3892/mmr.2021.12126

Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway

Authors:
- Weihong Wang
- Yukai He
- Qiuli Liu
View Affiliations

Affiliations: Department of Hepatology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China
Published online on: April 29, 2021 https://doi.org/10.3892/mmr.2021.12126
Article Number: 487
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metabolic dysfunction‑associated fatty liver disease (MAFLD) is a serious threat to human health. Parthenolide (PAR) displays several important pharmacological activities, including the promotion of liver function recovery during hepatitis. The aim of the present study was to assess the effect of PAR on MAFLD in a mouse model. Body weight, liver to body weight ratios, histological score, alanine transaminase, aspartate transaminase, total cholesterol and triglyceride levels were determined to evaluate liver injury. Liver hydroxyproline concentrations were also assessed. The expression levels of lipid metabolism‑related genes (sterol regulatory element binding protein‑1c, fatty acid synthase, acetyl CoA carboxylase 1, stearoyl CoA desaturase 1 and carbohydrate response element‑binding protein, peroxisome proliferator‑activated receptor α, carnitine palmitoyl transferase 1α and acyl‑CoA dehydrogenase short chain), liver fibrosis‑associated genes (α‑smooth muscle actin, tissue inhibitor of metalloproteinase 1 and TGF‑β1), pro‑inflammatory cytokines (TNF‑α, IL‑1β and IL‑6) and oxidative stress‑associated enzymes (malondialdehyde, superoxide dismutase and glutathione peroxidase) were measured in mice with MAFLD. The expression levels of genes associated with the HIPPO pathway were also measured. In vivo experiments using a specific inhibitor of HIPPO signalling were performed to verify the role of this pathway in the effects of PAR. PAR exerted beneficial effects on liver injury, lipid metabolism, fibrosis, inflammation and oxidative stress in mice with MAFLD, which was mediated by activation of the HIPPO pathway.

View Figures

View References

1	Tilg H and Effenberger M: From NAFLD to MAFLD: When pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 17:387–388. 2020. View Article : Google Scholar : PubMed/NCBI
2	Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M and Azarbayjani MA: Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. Eur J Sport Sci. 19:994–1003. 2019. View Article : Google Scholar : PubMed/NCBI
3	Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al: A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 73:202–209. 2020. View Article : Google Scholar : PubMed/NCBI
4	Eslam M and George J: Reply to: Correspondence on ‘A new definition for metabolic associated fatty liver disease: An international expert consensus statement’: MAFLD: Moving from a concept to practice. J Hepatol. 73:1268–1269. 2020. View Article : Google Scholar : PubMed/NCBI
5	Eslam M, Valenti L and Romeo S: Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 68:268–279. 2018. View Article : Google Scholar : PubMed/NCBI
6	Jegatheesan P and De Bandt JP: Fructose and NAFLD: The multifaceted aspects of fructose metabolism. Nutrients. 9:2302017. View Article : Google Scholar : PubMed/NCBI
7	Bellentani S: The epidemiology of non-alcoholic fatty liver disease. Liver Int. 37 (Suppl 1):81–84. 2017. View Article : Google Scholar : PubMed/NCBI
8	Rotman Y and Sanyal AJ: Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 66:180–190. 2017. View Article : Google Scholar : PubMed/NCBI
9	Van De Wier B, Koek GH, Bast A and Haenen GR: The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr. 57:834–855. 2017. View Article : Google Scholar : PubMed/NCBI
10	Liu C, Liao JZ and Li PY: Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease. World J Gastroenterol. 23:1964–1973. 2017. View Article : Google Scholar : PubMed/NCBI
11	Duan D, Zhang J, Yao J, Liu Y and Fang J: Targeting thioredoxin reductase by parthenolide contributes to inducing apoptosis of HeLa cells. J Biol Chem. 291:10021–10031. 2016. View Article : Google Scholar : PubMed/NCBI
12	Wang D, Wang H, Fu S, Cheng X, Yang F, Zhang Q, Li Y, Xue Z, Zhang L, Huang W, et al: Parthenolide ameliorates Concanavalin A-induced acute hepatitis in mice and modulates the macrophages to an anti-inflammatory state. Int Immunopharmacol. 38:132–138. 2016. View Article : Google Scholar : PubMed/NCBI
13	Barbier-Torres L, Beraza N, Fernández-Tussy P, Lopitz-Otsoa F, Fernández-Ramos D, Zubiete-Franco I, Varela-Rey M, Delgado TC, Gutiérrez V, Anguita J, et al: Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1. Hepatology. 62:1237–1248. 2015. View Article : Google Scholar : PubMed/NCBI
14	Bahabadi M, Mohammadalipour A, Karimi J, Sheikh N, Solgi G, Goudarzi F, Hashemnia M and Khodadadi I: Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease. Immunopharmacol Immunotoxicol. 39:233–242. 2017. View Article : Google Scholar : PubMed/NCBI
15	Patel SH, Camargo FD and Yimlamai D: Hippo signaling in the liver regulates organ size, cell fate, and carcinogenesis. Gastroenterology. 152:533–545. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zhou Y, Lv X, Qu H, Zhao K, Fu L, Zhu L, Ye G and Guo J: Differential expression of circular RNAs in hepatic tissue in a model of liver fibrosis and functional analysis of their target genes. Hepatol Res. 49:324–334. 2019. View Article : Google Scholar : PubMed/NCBI
17	Fujisawa K, Takami T, Sasai N, Matsumoto T, Yamamoto N and Sakaida I: Metabolic alterations in spheroid-cultured hepatic stellate cells. Int J Mol Sci. 21:34512020. View Article : Google Scholar : PubMed/NCBI
18	Yi M, Li J, Chen S, Cai J, Ban Y, Peng Q, Zhou Y, Zeng Z, Peng S, Li X, et al: Correction to: Emerging role of lipid metabolism alterations in Cancer stem cells. J Exp Clin Cancer Res. 37:1552018. View Article : Google Scholar : PubMed/NCBI
19	Kodama T, Yi J, Newberg JY, Tien JC, Wu H, Finegold MJ, Kodama M, Wei Z, Tamura T, Takehara T, et al: Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proc Natl Acad Sci USA. 115:E10417–E10426. 2018. View Article : Google Scholar : PubMed/NCBI
20	Lopez-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, Blanco J, Egido J and Gómez-Guerrero C: Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol. 26:1864–1870. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kim SL, Liu YC, Seo SY, Kim SH, Kim IH, Lee SO, Lee ST, Kim DG and Kim SW: Parthenolide induces apoptosis in colitis-associated colon cancer, inhibiting NF-κB signaling. Oncol Lett. 9:2135–2142. 2015. View Article : Google Scholar : PubMed/NCBI
22	Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Wang M and Li Q: Parthenolide could become a promising and stable drug with anti-inflammatory effects. Nat Prod Res. 29:1092–1101. 2015. View Article : Google Scholar : PubMed/NCBI
25	Liao K, Xia B, Zhuang QY, Hou MJ, Zhang YJ, Luo B, Qiu Y, Gao YF, Li XJ, Chen HF, et al: Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-κB/COX-2 pathway. Theranostics. 5:302–321. 2015. View Article : Google Scholar : PubMed/NCBI
26	Li XH, Xiao T, Yang JH, Qin Y, Gao JJ, Liu HJ and Zhou HG: Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-κB/Snail signaling pathway. Respir Res. 19:1112018. View Article : Google Scholar : PubMed/NCBI
27	Machado MV, Michelotti GA, Pereira TA, Xie G, Premont R, Cortez-Pinto H and Diehl AM: Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J Hepatol. 63:962–970. 2015. View Article : Google Scholar : PubMed/NCBI
28	Chen P, Luo Q, Huang C, Gao Q, Li L, Chen J, Chen B, Liu W, Zeng W and Chen Z: Pathogenesis of non-alcoholic fatty liver disease mediated by YAP. Hepatol Int. 12:26–36. 2018. View Article : Google Scholar : PubMed/NCBI
29	Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J and Bugianesi E: Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 15:11–20. 2018. View Article : Google Scholar : PubMed/NCBI
30	Berdan CA, Ho R, Lehtola HS, To M, Hu X, Huffman TR, Petri Y, Altobelli CR, Demeulenaere SG, Olzmann JA, et al: Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells. Cell Chem Biol. 26:1027–1035 e22. 2019. View Article : Google Scholar : PubMed/NCBI
31	Wu CT, Deng JS, Huang WC, Shieh PC, Chung MI and Huang GJ: Salvianolic acid C against acetaminophen-induced acute liver injury by attenuating inflammation, oxidative stress, and apoptosis through inhibition of the Keap1/Nrf2/HO-1 signaling. Oxid Med Cell Longev. 2019:90568452019. View Article : Google Scholar : PubMed/NCBI
32	Xia SF, Shao J, Zhao SY, Qiu YY, Teng LP, Huang W, Wang SS, Cheng XR and Jiang YY: Niga-ichigoside F1 ameliorates high-fat diet-induced hepatic steatosis in male mice by Nrf2 activation. Food Funct. 9:906–916. 2018. View Article : Google Scholar : PubMed/NCBI
33	Rui L: Energy metabolism in the liver. Compr Physiol. 4:177–197. 2014. View Article : Google Scholar : PubMed/NCBI
34	Makled MN, Sharawy MH and El-Awady MS: The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin. Naunyn Schmiedebergs Arch Pharmacol. 392:1569–1576. 2019. View Article : Google Scholar : PubMed/NCBI
35	Zhang Y, Miao H, Guan H, Wang C, Wang Z and Ji L: Long-term diosbulbin B treatment induced liver fibrosis in mice. Chem Biol Interact. 298:15–23. 2019. View Article : Google Scholar : PubMed/NCBI
36	Li S, Gao X, Wu X, Wu Z, Cheng L, Zhu L, Shen D and Tong X: Parthenolide inhibits LPS-induced inflammatory cytokines through the toll-like receptor 4 signal pathway in THP-1 cells. Acta Biochim Biophys Sin (Shanghai). 47:368–375. 2015. View Article : Google Scholar : PubMed/NCBI
37	Paolucci EM, Loukov D, Bowdish DME and Heisz JJ: Exercise reduces depression and inflammation but intensity matters. Biol Psychol. 133:79–84. 2018. View Article : Google Scholar : PubMed/NCBI
38	Min YN, Niu ZY, Sun TT, Wang ZP, Jiao PX, Zi BB, Chen PP, Tian DL and Liu FZ: Vitamin E and vitamin C supplementation improves antioxidant status and immune function in oxidative-stressed breeder roosters by up-regulating expression of GSH-Px gene. Poult Sci. 97:1238–1244. 2018. View Article : Google Scholar : PubMed/NCBI
39	Kim CY, Jung YW and Park JS: Parthenolide, a feverfew-derived phytochemical, ameliorates obesity and obesity-induced inflammatory responses via the Nrf2/Keap1 pathway. Pharmacol Res. 145:1042592019. View Article : Google Scholar : PubMed/NCBI
40	Ardestani A, Lupse B and Maedler K: Hippo signaling: Key emerging pathway in cellular and whole-body metabolism. Trends Endocrinol Metab. 29:492–509. 2018. View Article : Google Scholar : PubMed/NCBI
41	Johnson RL: Hippo signaling and epithelial cell plasticity in mammalian liver development, homeostasis, injury and disease. Sci China Life Sci. 62:1609–1616. 2019. View Article : Google Scholar : PubMed/NCBI
42	Jeong SH, Kim HB, Kim MC, Lee JM, Lee JH, Kim JH, Kim JW, Park WY, Kim SY, Kim JB, et al: Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. J Clin Invest. 128:1010–1025. 2018. View Article : Google Scholar : PubMed/NCBI